PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Creative Commons License

Muselaers S., ERDEM S., Bertolo R., Ingels A., KARA Ö., Pavan N., ...Daha Fazla

JOURNAL OF CLINICAL MEDICINE, cilt.11, sa.7, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 11 Sayı: 7
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3390/jcm11071829
  • Dergi Adı: JOURNAL OF CLINICAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: PSMA PET, CT, renal cell carcinoma, kidney cancer, imaging, MEMBRANE ANTIGEN, F-18-DCFPYL PET/CT, F-18-FDG PET/CT, TOMOGRAPHY, EXPRESSION, NEOVASCULATURE, RECURRENCE, TRACER, TUMORS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.